Clinical presentations and standard therapy of AIDS-associated Kaposi's sarcoma

Hematology/Oncology Clinics of North America

Volumn 17, Issue 3, 2003, Pages 747-762

  Von Roenn, Jamie H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CYTOTOXIC AGENT; DAUNORUBICIN; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; INTERFERON; NAVELBINE; PACLITAXEL; RETINOID; TETRADECYL SULFATE SODIUM; VINBLASTINE; VINCRISTINE; ZIDOVUDINE;

AIDS RELATED COMPLEX; ALOPECIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CRYOTHERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOCOMPETENCE; INFECTION CONTROL; KAPOSI SARCOMA; LIVER TOXICITY; LOCAL THERAPY; LONG TERM CARE; MORTALITY; MOUTH DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RASH; REVIEW; SKIN DEFECT; SYSTEMIC THERAPY; VIRUS LOAD; VIRUS REPLICATION;

EID: 0038386884     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00043-1     Document Type: Review

References (76)

1. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92: 1823-30.
2. Eltom MA, Hemal A, Mbulaiteye SM, et al. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002;94: 1204-10.
3. Grulich AE, Li Y, McDonald AM, et al. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001;15: 629-33.
4. Jones JL, Hanson DL, Dworkin MS, Jaffe HW. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr 2000;24:270-4.
5. Jacobson LP, Yamashita TE, Detels R, et al, for the Multicenter AIDS Cohort Study. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma among HIV-1-infected individuals. J Acquir Immune Defic Syndr 1999;21: S34-41.
6. Niedt GW, Schinella RA. Acquired immunodeficiency syndrome: clinicopathologic study of 56 autopsies. Arch Pathol Lab Med 1985;109:727-34.
7. Huang L, Schnapp LM, Gruden JF, et al. Presentation of AIDS-related pulmonary Kaposi's sarcoma diagnosed by bronchoscopy. Am J of Respir and Crit Care 1996;153:1385-90.
8. Ioachim HL, Adsay V, Giancotti FR, et al. Kaposi's sarcoma of internal organs. A multiparameter study of 86 cases. Cancer 1995;15:1376-85.
9. Rosella M, Masotti A, Cottoni F. Endoscopic examination in Kaposi's sarcoma. J Eur Acad Dermatol Venereol 2000;14:225-6.
10. Friedman-Kien AE, Saltzman BR. Clinical manifestations of classical, endemic African and epidemic AIDS-associated Kaposi's sarcoma. J Am Acad Dermatol 1990;22:1237-50.
11. Bini ED, Micale PI, Weinshal EH. Risk factors for rebleeding and mortality from acute upper gastrointestinal hemorrhage in human immunodeficiency virus infection. Am J Gastroenterol 1999;94:358-63.
12. Meduri GU, Stover DE, Lee M, et al. Pulmonary Kaposi's sarcoma in the acquired immune deficiency syndrome: clinical, radiographic, and pathologic manifestations. Am J Med 1986;81: 11-8.
13. Judson MA, Sahn SA. Endobronchial lesions in HIV-infected individuals. Chest 1994;105: 1314-23.
14. Light RW, Hamm H. Pleural disease and acquired immune deficiency syndrome. Eur Respir J 1997;10:2638-43.
15. Beck JM. Pleural disease in patients with acquired immune deficiency syndrome. Clin Chest Med 1998;19:341-9.
16. O'Brien RF, Cohn DL. Serosanguineous pleural effusions in AIDS-associated Kaposi's sarcoma. Chest 1989;96:460-6.
17. Gamborino E, Carrilho C, Ferro J, et al. Fine-needle aspiration diagnosis of Kaposi's sarcoma in a developing country. Diagn Cytopathol 2000;23:322-5.
18. Nuovo M, Nuovo G. Utility of HHV8 RNA detection for differentiating Kaposi's sarcoma from its mimics. J Cutan Pathol 2001;28:248-55.
19. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response and staging criteria. J Clin Oncol 1989;7:1201-7.
20. Krown S, Testa M, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997;15:3085-92.
21. Barillari G, Gendelman R, Gallo RC, Ensoli B. The Tat protein of human immunodeficiency virus type I, a growth factor for AIDS Kaposi's sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 1993;90:7941-5.
22. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
23. Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996;335:233-41.
24. Rady PL, Yen A, Rollefson JL, et al. Herpesvirus-like DNA sequences in non-Kaposi's sarcoma skin lesions of transplant patients. Lancet 1995;345:1339-40.
25. Moore PS, Kingsley LA, Holmberg SD, et al. Kaposi's sarcoma-associated herpesvirus infection prior to the onset of Kaposi's sarcoma. AIDS 1996;10:175-80.
26. Looney DJ, Wikthe W, Feigal E, et al. Relationship of HHV-8 peripheral blood mononuclear cell burden to immunodeficiency, opportunistic infections, response to therapy and stage of Kaposi's sarcoma [abstract 75]. 1st Natl AIDS Malignancy Conference, Bethesda, MD. J Acquir Immune Defic Syndr 1997;14:A35.
27. Mendez JC, Procop GW, Espy MJ, Paya CV, Smith TF. Detection and semiquantitative analysis of human herpesvirus 8 DNA in specimens from patients with Kaposi's sarcoma. J Clin Microbiol 1998;36:2220-2.
28. Nunez M, Machuca A, Soriano V, Podzamczer D, Gonzalez-Lahoz J. Clearance of human herpesvirus type 8 viraemia in HIV-1 positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. Caelyx/KS Spanish Study Group. AIDS 2000;14:913-9.
29. Caterino-de-Araujo A, Carbone PHL, Martinelli FLB, et al. Absence of an association between the presence of human herpesvirus 8 antibodies and the development of Kaposi's sarcoma in HIV-1-infected patients receiving antiretroviral therapy. AIDS 2000;14:1455-7.
30. Leao JC, Kumar NP, McLean KA, et al. Effect of HIV-1 protease inhibitors on the clearance of HHV-8 from blood of HIV-1 infected patients. J Med Virol 2000;62:416-20.
31. Rizzieri DA, Liu J, Traweek ST, Miralles GD. Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor. Lancet 1997;349:774-5.
32. Mesri EA. Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpes-virus/HHV8: a missing link in the pathogenesis of acquired immune deficiency syndrome-associated Kaposi's sarcoma. Blood 1999;93:4031-3.
33. Dezube BJ. The role of human immunodeficiency virus-I in the pathogenesis of acquired immunodeficiency syndrome-related Kaposi's sarcoma: the importance of an inflammatory and angiogenic milieu. Semin Oncol 2000;27:420-2.
34. Pati S, Pelser CB, Dufraine J, et al. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002;99:3771-9.
35. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002;8:225-32.
36. Holkova B, Takeshita K, Cheng DM, et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 2001;19:3848-51.
37. Tam HK, Zuo-Feng Z, Jacobson LP, et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002;98:916-22.
38. Flaitz CM, Nichols CM, Hicks MJ. Role of intralesional vinblastine administration in treatment of intraoral Kaposi's sarcoma in AIDS. Eur J Cancer 1995;31B:280-5.
39. Ramirez-Amador V, Esquivel-Pedraza L, Lozada-Nur F, et al. Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial. Oral Oncol 2002;38:460-7.
40. Webster GF. Local therapy for mucocutaneous Kaposi's sarcoma in patients with acquired immunodeficiency syndrome. Dermatol Surg 1995;21:205-8.
41. Stelzer KJ, Griffin TW. A randomized prospective trial of radiation therapy for AIDS associated Kaposi's sarcoma. Int J Radiat Oncol 1993;27:1057-61.
42. Piedbois P, Frikha H, Martin L, et al. Radiotherapy in the management of epidemic Kaposi's sarcoma. Int J Radiat Oncol 1994;30:1207-11.
43. Swift PS. Radiation therapy in the management of HIV-related KS. Hematol Oncol Clin North Am 1996;10:1069-80.
44. Guo W-X, Gill PS, Antakly T. Inhibition of AIDS-Kaposi's sarcoma cell proliferation following retinoic acid receptor activation. Cancer Res 1995;55:823-9.
45. Cai J, Masood R, Lin G, et al. Retinoic acid inhibits AIDS-Kaposi's sarcoma tumor cell growth in vivo and in vitro [abstract]. Blood 1992;80(Suppl):S327A.
46. Nagpal S, Cai J, Zheng T, et al. Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma. Mol Cell Biol 1997;17:4159-68.
47. Bodsworth NJ, Bloch M, Bower M, et al. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol 2001;2:77-87.
48. Duvic M, Friedman-Kien AE, Looney DJ, et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. Arch Dermatol 2000;136:1461-9.
49. Volberding PA, Mitsuyasu RT, Golando JP, et al. Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A). Cancer 1987;59:620-5.
50. Mauss S, Jablonowski H. Efficacy, safety, and tolerance of low-dose, long-term interferon alpha-2b and zidovudine in early stage AIDS-associated Kaposi's sarcoma. J Acquir Immune Defic Syndr 1995;10:157-62.
51. Fischl MA, Finkelstein DM, He W, et al. A phase II study of recombinant human interferon alpha-2b and zidovudine in patients with AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr 1996;11:379-85.
52. Shepherd FA, Beaulieu R, Gelmon K, et al. Prospective randomized trial of two dose levels of interferon alpha with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network Study. J Clin Oncol 1998;16:1736-42.
53. Krown SE, Gold JWM, Niedzwiecki D, et al. Interferon-α with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;112:812-21.
54. Krown SE, Ping Li, Von Roenn JH, et al. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS Clinical Trials Group Study. J Interferon Cytokine Res 2002;22:295-303.
55. Paredes J, Kahn JO, Tong WP, et al. Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: a phase 1 multicenter trial of the AIDS Clinical Trials Group. J Acquir Immune Defic Syndr 1995;9:138-44.
56. Volberding PA, Abrams DI, Conant M, et al. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:335-8.
57. Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol 2002;20:3236-41.
58. Remick SC, Reddy M, Herman D, et al. Continuous infusion bleomycin in AIDS-related Kaposi's sarcoma. J Clin Oncol 1994;12:1130-6.
59. Saville MW, Lietzau J, Pluda JM, et al. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 1995;346:26-8.
60. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 1997;17:1876-83.
61. Bogner JR, Kronawitter U, Rolinski B, et al. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr 1994;7:463-8.
62. Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 1995;13:914-20.
63. Presant CA, Scolaro M, Kennedy P, et al. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 1993;341:1242-3.
64. Tulpule A, Yung RC, Wernz J, et al. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. J Clin Oncol 1998;16:3369-74.
65. Gill PS, Rarick MU, Espina B, et al. Advanced acquired immunodeficiency syndrome-related Kaposi's sarcoma: results of pilot studies using combination chemotherapy. Cancer 1990;65: 1074-8.
66. Rosenthal E, Poizot-Martin I, Santi-Marc T, Spano JP, Cacoub P. DNX Study Group. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. Am J Clin Oncol 2002;25:57-9.
67. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS related Kaposi's sarcoma. J Clin Oncol 1996; 14:2353-64.
68. Fumagalli L, Zucchetti M, Parisi I, et al. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. Cancer Chemother Pharmacol 2000;45:495-501.
69. Cadranel JL, Kammoun S, Chevret S, et al. Results of chemotherapy in 30 AIDS patients with symptomatic pulmonary Kaposi's sarcoma. Thorax 1994;49:958-60.
70. Northfelt DW, Dezube B, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-51.
71. Stewart JSW, Jabonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 1998;16:683-91.
72. Mitsuyasu R, Von Roenn J, Krown S, et al. Comparison study of liposomal doxorubicin (DOX) alone or with bleomycin and vincristine (DBV) for treatment of advanced AIDS-associated Kaposi's sarcoma (AIDS-KS): AIDS Clinical Trials Group (ACTG) protocol 286 [abstract]. Proc Am Soc Clin Oncol 1997;16:55a.
73. Girard PM, Bouchaud O, Guetschel A, et al. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated Kaposi's Sarcoma. AIDS 1996;10:753-7.
74. Laubenstein LS, Krigel RL, Odajnyk CM, et al. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastine. J Clin Oncol 1984;2: 1115-20.
75. Nasti G, Errante D, Talamini R, et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study. J Clin Oncol 2000;18:1550-7.
76. Brambilla L, Labianca R, Ferrucci SM, Taglioni M, Boneschi V. Treatment of classical Kaposi's sarcoma with gemcitabine. Dermatology 2001;202:119-22.